Reply to Goel et al. 'TP53 mutation allele-burden and disease outcome in MDS/AML'

Affiliations

Comment

D A Sallman et al. Leukemia. 2017 Mar.

. 2017 Mar;31(3):767-768.

doi: 10.1038/leu.2016.257. Epub 2016 Oct 14.

¹ Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

No abstract available

Comment on

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA, Komrokji R, Vaupel C, Cluzeau T, Geyer SM, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Sallman DA, et al. Leukemia. 2016 Mar;30(3):666-73. doi: 10.1038/leu.2015.304. Epub 2015 Oct 30. Leukemia. 2016. PMID: 26514544 Free PMC article.
High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort.
Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I, Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski JP, Braunschweig I, Verma A. Goel S, et al. Leukemia. 2016 Aug;30(8):1793-5. doi: 10.1038/leu.2016.74. Epub 2016 Apr 29. Leukemia. 2016. PMID: 27125205 No abstract available.